PGJ Performance — Invesco Golden Dragon China ETF
Data updated: 2026-09-28
PGJ returned −11.32% year to date and −10.03% over one year to Jul 2026. Annualised returns are −3.92% over 3 years and −9.60% over 5 years. The fund trailed its China Equity category average: $100 invested three years ago grew to $89, against $134 for the category, and to $90 over one year, against $117. Volatility over the past three years was 28.53% a year. In the 12 months to Jul 2026 the fund lost a net $25.6M, and assets reached $98.35M.
PGJ Growth of $100
What $100 invested in Invesco Golden Dragon China ETF grew to, compounded from monthly returns reported on SEC Form N-PORT, against the China Equity category average over the same months.
| Period | PGJ | Category average |
|---|---|---|
| 1 year (Aug 2025 – Jul 2026) | $90 | $117 |
| 3 years (Aug 2023 – Jul 2026) | $89 | $134 |
| 5 years (Aug 2021 – Jul 2026) | $60 | $98 |
| Since data start (Aug 2019 – Jul 2026) | $79 | $138 |
PGJ Trailing Returns
Total returns to Jul 2026, from SEC N-PORT.
| Period | Total return |
|---|---|
| YTD | −11.32% |
| 1 year | −10.03% |
| 3 years (annualised) | −3.92% |
| 5 years (annualised) | −9.60% |
PGJ Annual Returns
Calendar-year total returns of Invesco Golden Dragon China ETF, compounded from monthly SEC N-PORT returns. Partial years show the months covered.
| Year | Total return |
|---|---|
| 2026 (Jan–Jul) | −11.32% |
| 2025 | +13.72% |
| 2024 | +5.88% |
| 2023 | −2.45% |
| 2022 | −24.35% |
| 2021 | −42.75% |
| 2020 | +53.58% |
| 2019 (Aug–Dec) | +14.74% |
PGJ Monthly Returns
Monthly total returns as reported on SEC Form N-PORT.
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | +2.7% | −5.9% | −7.1% | +3.3% | −4.8% | −11.1% | +13.0% | — | — | — | — | — |
| 2025 | +4.4% | +8.7% | 0.0% | −9.1% | +1.7% | +4.6% | +2.1% | +6.2% | +9.4% | −4.1% | −5.8% | −3.3% |
| 2024 | −14.2% | +12.3% | −1.9% | +1.2% | +2.7% | −9.1% | −1.5% | −0.5% | +29.8% | −4.5% | −3.5% | +1.1% |
| 2023 | +17.9% | −11.0% | +3.6% | −9.8% | −8.8% | +9.5% | +19.9% | −10.3% | −5.4% | −6.3% | +3.9% | +0.5% |
| 2022 | −5.1% | −4.6% | −12.3% | −4.9% | +2.6% | +15.7% | −11.0% | +6.2% | −17.6% | −24.9% | +42.0% | +1.5% |
| 2021 | +8.9% | +7.6% | −14.7% | −0.2% | −5.6% | +1.8% | −22.0% | −1.6% | −9.9% | +5.0% | −5.3% | −13.1% |
| 2020 | −2.5% | +0.5% | −7.7% | +7.5% | +6.1% | +14.2% | +5.5% | +3.7% | −1.8% | +3.0% | +8.0% | +9.1% |
| 2019 | — | — | — | — | — | — | — | +1.1% | −2.5% | +7.0% | +3.1% | +5.6% |
PGJ Risk
Risk measures from monthly returns over Aug 2023 – Jul 2026.
- 3-year volatility (annualised): 28.53%
- 3-year Sharpe ratio: -0.30 (vs 4.5% risk-free rate)
- Best month: +29.82% (Sep 2024)
- Worst month: −14.18% (Jan 2024)
PGJ Fund Flows
Monthly money in and out of Invesco Golden Dragon China ETF, from SEC Form N-PORT.
- 12-month net flow: −$25.6M
- 12-month gross sales (incl. reinvestments): $9.0M
- Sales ÷ redemptions: 0.26×
| Month | Sales | Redemptions | Net flow |
|---|---|---|---|
| Jul 2026 | $464K | $2.0M | −$1.5M |
| Jun 2026 | $1.1M | $3.4M | −$2.3M |
| May 2026 | $0 | $7.1M | −$7.1M |
| Apr 2026 | $0 | $0 | $0 |
| Mar 2026 | $0 | $2.7M | −$2.7M |
| Feb 2026 | $0 | $6.8M | −$6.8M |
| Jan 2026 | $2.1M | $1.2M | $953K |
| Dec 2025 | $584K | $4.5M | −$3.9M |
| Nov 2025 | $0 | $5.4M | −$5.4M |
| Oct 2025 | $0 | $1.3M | −$1.3M |
| Sep 2025 | $4.7M | $308K | $4.4M |
| Aug 2025 | $0 | $0 | $0 |
PGJ Assets Under Management
Net assets of Invesco Golden Dragon China ETF by report date, from SEC N-PORT filings.
| Report date | Net assets |
|---|---|
| 2026-07-31 | $98.35M |
| 2026-04-30 | $114.65M |
| 2026-01-31 | $136.80M |
| 2025-10-31 | $156.13M |
| 2025-07-31 | $139.61M |
| 2025-04-30 | $141.91M |
| 2025-01-31 | $139.75M |
| 2024-10-31 | $165.05M |
| 2024-07-31 | $121.77M |
| 2024-04-30 | $147.45M |
| 2024-01-31 | $126.18M |
| 2023-10-31 | $158.18M |
For information only. Not investment advice: figures are as reported in SEC filings and may contain errors or be out of date. Past performance does not guarantee future results.